Business Context and Reporting Period
Company: Oragenics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 10, 2016
Event: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard.
Key Financial Metrics
The filing provides limited financial data, focusing on equity compliance:
- Stockholders' Equity (as of Dec 31, 2015): $4.7 million.
- Required Equity Threshold: $6.0 million (per NYSE MKT Section 1003(a)(iii) for companies with reported losses).
- Revenue, Profit, Cash Flow, Debt: The filing text does not provide a clear value for these metrics.
Material Changes and Compliance Status
On May 10, 2016, the Company received a Deficiency Letter from NYSE MKT LLC stating non-compliance with continued listing standards due to insufficient stockholders' equity. The Company's equity of $4.7 million fell below the required $6.0 million threshold.
- Trading Symbol: "OGEN" will continue to trade but with an added ".BC" designation to indicate non-compliance.
- Operational Impact: The notification does not affect business operations, SEC reporting requirements, or trigger defaults under material agreements.
Guidance, Outlook, and Contingencies
Compliance Plan Deadline: The Company must submit a plan to NYSE MKT by June 10, 2016, detailing actions to regain compliance by November 10, 2017.
Management Intent: The Company intends to submit the required plan by the June 10, 2016 deadline.
Risks: If the Company fails to submit a plan, the plan is not accepted, or compliance is not regained by the deadline, NYSE MKT may commence delisting procedures.
Investor Verification Checklist
- Verify the submission of the compliance plan by the June 10, 2016 deadline.
- Monitor the ".BC" trading designation on the stock symbol "OGEN".
- Review the attached press release (Exhibit 99.1) for additional details on the non-compliance notice.
- Check future filings for updates on the Company's strategy to increase stockholders' equity to the $6.0 million threshold.